Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

New Look at Breast Cancer Cell Line Sheds Light on Structural Complexity

Thursday, September 6, 2018

In an exciting paper that made the cover of Genome Research, scientists from Cold Spring Harbor Laboratory and collaborating institutions report the genome sequence and transcriptome of a commonly used breast cancer cell line. They determined that the cell line harbors far more structural variants than previously thought with results that call into question cancer genome analysis based solely on short-read sequencing data.

In “Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line,” lead author Maria Nattestad, senior author Michael Schatz, and collaborators describe an in-depth investigation of SK-BR-3, an important model for HER2-positive breast cancer. “SK-BR-3 is known to be highly rearranged, although much of the variation is in complex and repetitive regions that may be underreported,” they write, explaining their choice of PacBio long-read sequencing to conduct a new genomic and transcriptomic analysis of the cell line.

Investigating genomic instability is essential to understanding cancer but attempts to do so using short-read sequencing have seen limited success due to challenges in detecting structural variation. Even large-scale cancer projects “have performed somewhat limited analysis of structural variations, as both the false positive rate and the false negative rate for detecting structural variants from short reads are reported to be 50% or more,” Nattestad, et al. report. “Furthermore, the variations that are detected are rarely close enough to determine whether they occur in phase on the same molecule, limiting the analysis of how the overall chromosome structure has been altered.”

With the goal of creating a comprehensive map of structural variations in cancer, scientists sequenced the SK-BR-3 genome using SMRT Sequencing. To enable comparison between sequencing technologies, they also used a short-read technology. The team found that PacBio data was more mappable: more than 90% of PacBio reads align with a mapping quality of 60, while just 69% of short reads did the same. “We also observed a smaller GC bias in the PacBio sequencing compared to the Illumina sequence data,” they note, “which enables more robust copy number analysis and generally better variant detection overall.”

An analysis of variants showed that long-read sequencing detected more than 17,000 structural variants of at least 50 bp in length, while the short-read data yielded only about 4,100, a difference that could largely be attributed to the lack of insertions called in the latter data set.  This closely mirrors the results of researchers working on population-specific reference genomes.

The scientists coupled their genomic variant discovery with the Iso-Seq method to capture full-length transcripts from SK-BR-3, noting that short-read data often cannot span or accurately reconstruct entire isoforms. “Long reads overcome such limitations by spanning multiple exon junctions and often covering complete transcripts,” they explain. Within the transcriptome analysis, the team closely examined several gene fusions. Some of the gene fusions were found to be the product of two or three rearrangement events occurring in sequence. For example, “CYTH1-EIF3H had been discovered previously with RNA-seq and been validated with RT-PCR, but it was not known to be a “2-hop” gene fusion (taking place through a series of two variants) until now,” the scientists report.  “This fusion was also captured in full by several individual SMRT-seq reads that contain both variants and have alignments in both genes.”  The authors also report finding direct evidence that a gene fusion previously thought to be the result of a 2-hop path is actually a 3-hop fusion.

One detailed illustration of the careful analysis performed for this project involved the ERBB2 oncogene, which is also called HER2. “We discover a complex sequence of nested duplications and translocations, suggesting a punctuated progression,” the team writes. They were able to “reconstruct the progression of rearrangements resulting in the amplification of the ERBB2 oncogene, including a previously unrecognized inverted duplication spanning a large portion of the region.”

“Long-read read sequencing can expose complex variants with great certainty and context, suggesting that more multi-hop gene fusions, inverted duplications, and complex events may be found in other cancer genomes,” the scientists conclude. “There may be many other types of complex variations present in other cancer genomes that were not found in SK-BR-3, so it is essential to continue building a catalogue of these variant types using the best available technologies.”

For more information, check out our profile of Schatz and Nattestad, or read up on the long-read analysis tools developed by this team.

Subscribe for blog updates: